Clinical trials: Lymphomas Non-Hodgkin's B-Cell
Primary Central Nervous System Lymphoma
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
This study aims to observe and explore the efficacy and safety of Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) regimen as first-line therapy for primary central nervous system diffuse large B-cell lymphomas(PCNS DLBCL)
- Trial name
- NCT06832267
- Testing
- Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Leukemia, Lymphoma
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00012207
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05936229
- Testing
- Interferon Beta-1A, X-Ray Imaging, Echocardiography
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02576275
- Testing
- Duvelisib, Rituximab, Bendamustine
- Where
- 7 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- SecuraBio
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
The goal of this clinical trial is to evaluate the efficacy and safety of early secondary infusion of CD19 CAR T-cell therapy in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), guided by ctDNA monitoring.
- Trial name
- NCT06902012
- Testing
- Infusion of Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhujiang Hospital
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma.
- Trial name
- EpcoReal (NCT06830759)
- Where
- 73 sites in Argentina, Australia and 11 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells
Quality Of Life and Drug Use in Patients With CAR-T Cells
CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more.
- Trial name
- QOLD CAR-T (NCT04914091)
- Testing
- Semi-structured interviews and self-administered questionnaires
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT02112526
- Testing
- Acalabrutinib
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Acerta Pharma BV
Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma
Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase II clinical trial aims at evaluating the efficacy and safety of azacitidine followed by rituximab-GDP immunochemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Trial name
- EPIC (NCT03719989)
- Testing
- azacitidine plus R-GDP
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Seoul National University Hospital
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Graft vs Host Disease, Myelodysplastic Syndromes
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of…
- Conditions
- Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid
- Trial name
- NCT00025662
- Testing
- RFT5-SMPT-dgA, Isolex system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19.
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT04665115
- Testing
- Ibrutinib, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Academic and Community Cancer Research United
B-cell Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse…
- Trial name
- NCT04313608
- Testing
- Glofitamab, Gemcitabine, Oxaliplatin
- Where
- 3 sites in Australia
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Relapsed Lymphoma
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2…
- Conditions
- Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma
- Trial name
- NCT01742988
- Testing
- fimepinostat, Rituximab, venetoclax
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Curis, Inc.
Lymphoma
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004908
- Testing
- cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Where
- United States
- Sponsor
- Northwestern University
Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous…
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma
- Trial name
- S-BR (NCT02623920)
- Testing
- Brentuximab, Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Arizona
Small Cell Lung Cancer, Uveal Melanoma
A Study of PLX2853 in Advanced Malignancies.
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
- Conditions
- Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT03297424
- Testing
- PLX2853
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Opna Bio LLC
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS)…
- Trial name
- NCT04609046
- Testing
- Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test
- Where
- 56 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
DLBCL, Diffuse Large B-Cell Lymphoma
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with…
- Trial name
- HiR+X (NCT06758037)
- Testing
- Drug therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in…
- Trial name
- NCT03843294
- Testing
- TAA-T cells, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Catherine Bollard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.